[1]于晓明,樊飞跃.肿瘤放射免疫疗法研究进展[J].国际放射医学核医学杂志,2006,30(2):80-83.
　YU Xiao-ming,FAN Fei-yue.Recent developments in radioimmunotherapy of tumor[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(2):80-83.
点击复制

肿瘤放射免疫疗法研究进展(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
30
期数:
2006年第2期
页码:
80-83
栏目:
实验核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Recent developments in radioimmunotherapy of tumor
作者:
于晓明;  樊飞跃
300192 天津, 中国医学科学院、中国协和医科大学放射医学研究所天津市分子核医学重点实验室
Author(s):
YU Xiao-ming;  FAN Fei-yue
Tianjin Key Laboratory of Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin 300192, China
关键词:
放射免疫疗法; 单克隆抗体; 淋巴瘤; 非霍奇金; 结肠肿瘤
Keywords:
Radioimmunotherapy; Monoantibody; Lyperglycinemia; non-Hodgkin; Colonic neoplasms
分类号:
R817.5
摘要:
放射免疫治疗是将针对肿瘤特异抗原的单克隆抗体用核素标记后,对肿瘤细胞进行的靶向治疗。在非霍奇金淋巴瘤的临床治疗中,放射免疫治疗已经成为一种常规的治疗手段。在实体瘤中,因为核素标记的单克隆抗体的定位很有限,所以限制了该疗法的使用。虽然如此,放射性核素标记的抗体在治疗微小病灶中的应用前景看好。
Abstract:
Radioimmunotherapy (RIT) is the therapy which targeted to tumor cells using radiolabeled monoclonal antibodies directed against tumor-associated antigens. It has been one of the standard treatment options for patients with non-Hodgkin’s lymphoma(NHL). The inefficient localization of radiolabeled mAbs to the solid tumors has refrained RIT from being applied to those diseases. Still, small volume or minimal residual disease has been recogenized as a potentially suitable target for radiolabeled antibodies. RIT appears promising for future cancer therapy.

参考文献/References:

1 Press OW.Physics for practitioners:the use of radiolabeled monoclonal antibodies in B-cell non-Hodgkin’s lymphoma.Semin Hematol,2000,37(4 Suppl 7):2-8.
2 Rennen HJ,Makarewicz J,Oyen WJ,et al.The effect of molecular weight on nonspecific accumulation of (99m)Tc-labeled proteins in inflammatory foci.Nucl Med Biol,2001,28(4):401-408.
3 Goldenberg DM.Targeted therapy of cancer with radiolabeled antibodies.J Nucl Med,2002,43(5):693-713.
4 Cardillo TM,Ying Z,Gold DV.Therapeutic advantage of (90)yttrium-versus (131)iodine-labeled PAM4 antibody in experimental pancreatic cancer.Clin Cancer Res.2001,7(10):3186-3192.
5 Koppe MJ,Bleichrodt RP,Soede AC,et al.Biodistribution and therapeutic efficacy of (125/131)I-,(186)Re-,(88/90)Y-,or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.J Nucl Med,2004,45(7):1224-1232.
6 DeNardo GL,Kroger LA,DeNardo S J,et al.Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3).Cancer,1994,73(3 suppl):1012-1022.
7 Griffiths GL,Govindan SV,Sharkey RM,et al. 90Y-DOTA-hLL2:An agent for radioimmunotherapy of non-Hodgkin’s lymphoma.J Nucl Med,2003,44(1):77-84.
8 Witzig TE,White CA,Wiseman GA,et al.Phase Ⅰ/Ⅱ trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+)B-cell non-Hodgkin’s lymphoma.J Clin Oncol,1999,17(12):3793-3803.
9 Witzig TE,Gordon LI,Cabanillas F,et al.Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade,follicular,or transformed B cell non-Hodgkin’s lymphoma.J Clin Oncol,2002,20(10):2453-2463.
10 Postema EJ.Dosimetry and radioimmunotherapy of non-Hodgkin’s lymphoma.J Nucl Med,2004,45(12):2126-2127.
11 Davis TA,Kaminski MS,Leonard JP,et al.The radioisotope contribute significantly to the activity of radioimmunotherapy.Clin Cancer Res,2004,10(23):7792-7798.
12 Postema EJ,Frielink C,Oyen WJ,et al.Biodistribution of 131I-, 186Re-, 177Lu-,and 88Y-labeled hLL2(Epratuzumab) in nude mice with CD22-positive lymphoma.Cancer Biother Radiopharm,2003,18(4):523-533.
13 Behr TM,Liersch T,Greiner-Bechert L,et al.Radioimmunotherapy of small-volume disease of metastatic colorectal cancer.Cancer,2002,94(4 suppl):1373-1381.
14 Wong JY,Shibata S,Williams LE,et al.A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.Clin Cancer Res,2003,9(16 Pt 1):5842-5852.
15 Meredith RF,Khazaeli MB,Plott WE,et al.Phase Ⅱ study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer.Clin Cancer Res,1996,2(11):1811-1818.
16 Koppe MJ,Soede AC,Pels W,et al.Experimental radioimmunotherapy of small peritoneal metastases of colorectal origin.Int J Cancer,2003,106(6):965-972.
17 Zanten-Przybysz I,Molthoff CF,Roos JC,et al.Influence of the route of administration on.targeting of ovarian cancer with the chimeric monoclonal antibody MOv18:i.v.vs.i.p.Int J Cancer,2001,92(1):106-114.
18 DeNardo SJ.Radioimmunodetection and therapy of breast cancer.Semin Nucl Med,2005,35(2):143-151.

相似文献/References:

[1]涂少华,陶嵘,沈江帆.单克隆抗体人源化技术研究进展[J].国际放射医学核医学杂志,2014,38(5):328.[doi:10.3760/cma.j.issn.1673-4114.2014.05.012]
　Tu Shao-hua,Tao Rong,Shen Jiang-fan.Advances on humanized monoclonal antibody technology[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):328.[doi:10.3760/cma.j.issn.1673-4114.2014.05.012]
[2]郭艾楠,魏玲格,傅鹏.131I-肿瘤细胞核人鼠嵌合单克隆抗体治疗实体瘤的研究进展[J].国际放射医学核医学杂志,2013,37(2):120.[doi:10.3760/cma.j.issn.1673-4114.2013.02.015]
　GUO Ai-nan,WEI Ling-ge,FU Peng.Advances on the treatment of solid tumor by 131I labeled mouse-human chimeric tumor necrosis therapy monoclanal antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):120.[doi:10.3760/cma.j.issn.1673-4114.2013.02.015]
[3]姚红霞,张金山.微波消融和131I-肿瘤细胞核人鼠嵌合单克隆抗体联合治疗肺癌[J].国际放射医学核医学杂志,2012,36(5):264.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.002]
　YAO Hong-xia,ZHA NG Jin-shan.Combination of microwave ablation and 131I labeled tumor necrosis therapy chimeric antibody in the treatment of lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(2):264.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.002]
[4]蒋宁一,熊玥.放射免疫导向治疗真菌感染灶的研究[J].国际放射医学核医学杂志,2008,32(3):137.
　JIANG Ning-yi,XIONG Yue.Research about the radioimmunotherapy of fungal infection[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(2):137.
[5]蔡秋琼,杜明华.131Ⅰ-rituximab治疗B细胞非霍奇金淋巴瘤[J].国际放射医学核医学杂志,2008,32(2):72.
　CAI Qiu-qiong,DU Ming-hua.131Ⅰ-rituximab therapy of B cell non-Hodgkin lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(2):72.
[6]冯春玲.放射免疫治疗中载体的研究进展[J].国际放射医学核医学杂志,2007,31(2):77.
　FENG Chun-ling.Research advances in carrier of radioimmunotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(2):77.
[7]魏莉,罗荣城.放射性核素标记抗CD20单克隆抗体治疗B细胞淋巴瘤的研究进展[J].国际放射医学核医学杂志,2006,30(3):153.
　WEI Li,LUO Rong-cheng.Advances in research of radioactive nuclide labeled anti-CD20 monoclonal antibody in B cell lymphomas[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(2):153.
[8]李敏杰.胰腺癌的放射免疫治疗进展[J].国际放射医学核医学杂志,2003,27(4):154.
　LI Min-jie.Radioimmunotherapy of pancreatic cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2003,27(2):154.
[9]杨卫东,朱承谟,吴祥甫.用基因工程技术制备多价微型抗体的研究[J].国际放射医学核医学杂志,1999,23(2):62.
　[J].International Journal of Radiation Medicine and Nuclear Medicine,1999,23(2):62.
[10]范义湘,彭武和,黄祖汉,等.放射免疫显像在大肠癌诊断中的应用进展[J].国际放射医学核医学杂志,1999,23(4):153.

备注/Memo

备注/Memo:
收稿日期:2006-01-05。
通讯作者:樊飞跃(E-mail:faithyfan@yahoo.com)
更新日期/Last Update: 1900-01-01